13F-HR/A filed by ACORN CAPITAL ADVISORS, LLC
ACORN CAPITAL ADVISORS, LLC filed this 13F-HR/A for the quarter ended 2025-03-31, filed 2025-05-19, with 22 holding rows worth $149,945,296.
- Accession
- 0001636587-25-000021
- Filer
- CIK 2054410
- Filed
- 2025-05-19
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2025
A holdings report, amendment of type restatement, 22 entries on the cover page, a total value of $149,945,296 stated on the cover page (in dollars after the unit check, H1), rows summing to $149,945,296 with VALUE read as dollars as filed, 13F file number 028-25253. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| CG ONCOLOGY INC | 156944100 | COMMON STOCK | 1,131,501 | $27,721,764 | dollars as filed | |
| UROGEN PHARMA LTD | M96088105 | COMMON STOCK | 1,516,303 | $16,770,311 | dollars as filed | |
| Y-mAbs Therapeutics Inc | 984241109 | Common Stock | 3,235,387 | $14,332,764 | dollars as filed | |
| TREVI THERAPEUTICS INC COM | 89532M101 | Stock | 2,144,844 | $13,491,069 | dollars as filed | |
| CANDEL THERAPEUTICS INC | 137404109 | COMMON STOCK | 2,152,252 | $12,160,224 | dollars as filed | |
| PUMA BIOTECHNOLOGY INC | 74587V107 | COMMON STOCK | 3,940,052 | $11,662,554 | dollars as filed | |
| BICARA THERAPEUTICS INC | 055477103 | COM | 643,382 | $8,383,262 | dollars as filed | |
| PROTARA THERAPEUTICS INC | 74365U107 | COM STK | 1,279,800 | $5,451,948 | dollars as filed | |
| TERNS PHARMACEUTICALS INC COM | 880881107 | Stock | 1,971,264 | $5,440,689 | dollars as filed | |
| ONKURE THERAPEUTICS INC | 68277Q105 | COM CL A | 1,439,674 | $5,123,781 | dollars as filed | |
| VERASTEM INC | 92337C203 | COMMON STOCK | 779,498 | $4,700,373 | dollars as filed | |
| CYBIN INC | 23256X407 | COM NEW | 734,394 | $4,663,402 | dollars as filed | |
| CARDIFF ONCOLOGY INC | 14147L108 | COM | 1,442,308 | $4,528,847 | dollars as filed | |
| OPTINOSE INC | 68404V209 | COM | 422,814 | $3,877,202 | dollars as filed | |
| WHITEHAWK THERAPEUTICS INC | 00032Q104 | CMN | 1,139,363 | $2,028,066 | dollars as filed | |
| X4 Pharmaceuticals, Inc. | 98420X103 | COM | 7,310,650 | $1,754,556 | dollars as filed | |
| MURAL ONCOLOGY PUB LTD CO | G63365103 | ORD SHS | 1,269,715 | $1,599,841 | dollars as filed | |
| AURA BIOSCIENCES INC | 05153U107 | COMMON STOCK | 590,508 | $1,453,362 | dollars as filed | |
| BIOATLA INC | 09077B104 | COM | 4,032,046 | $1,411,216 | dollars as filed | |
| Q32 BIO INC | 746964105 | Common Stock | 803,425 | $1,325,651 | dollars as filed | |
| VYNE THERAPEUTICS INC | 92941V308 | COM | 785,938 | $1,241,782 | dollars as filed | |
| ACRIVON THERAPEUTICS INC | 004890109 | CMN | 405,237 | $822,632 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001636587-25-000017 | superseded | 2025-05-15 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001636587-25-000021 | this filing | 2025-05-19 | acceptance time not in the bulk data set |